Product Description
for the treatment of mild to moderate atopic dermatitis with associated pruritus in adults
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Device
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Oculus Innovative Sciences, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Pruritus|Dermatitis, Atopic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01232985 |
MIC-AD-001 | P2 |
Completed |
Pruritus|Dermatitis, Atopic |
2010-12-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|